AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Telix Pharmaceuticals Limited (ASX: TLX) is a clinical-stage biopharmaceutical company focused on the development of products for the treatment of prostate, renal (kidney) and glioblastoma (brain) cancer.
On 22 May 2019, TLX released a transcript of CEO and Chairman address delivered at the companyâs Annual General Meeting.
In the past twelve months, Telix has witnessed a period of astonishing growth. Currently, TLX is clinically active in 17 countries with total numbers of 8 ongoing clinical trials either as company-sponsored trial or as a collaborator to an investigator-led study.
Some recently launched trials include ZIRCON Phase III trial for renal cancer imaging and IPAX-1 glioblastoma therapy study. It is reported that development in the activities has reached a point whereby each day, patients are benefitting from TLX technology.
Last 12 months performance of the company (Source: Companyâs Announcement)
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, acknowledged the efforts made by the entire team around the globe for achieving this scale of activity. The manufacturing and supply chain capabilities of the company have supported these clinical trials and have the potential to deliver products for multi-centre clinical trials while supporting early commercialisation of products on the back of sufficient scale.
A glimpse of merger and acquisition activities (Source: Companyâs Announcement)
Last year, TLX completed two acquisition to expand the global footprint and support the increments in the value of the company. Atlab Pharma SAS, a French company with extensive clinical data, was acquired to underpin the development of TLXâs prostate cancer therapy program and an intellectual property portfolio. It helps TLX in defending certain clinical applications around combination therapies with anti-androgen drugs. TLX believes that these anti-androgen drugs would be commercially important in the near future.
Advanced Nuclear Medicine Ingredients (ANMI) SA, was the second acquisition of TLX. Since, acquisition, ANMI has built a strong reputation in radiochemistry excellence and has developed extremely innovative products, which are to be added to Telix Portfolio. The acquisition has placed both companies as a leading urologic oncology imaging firm.
illumetTM has been one of success story for TLX in the past twelve months. Itâs a prostate imaging product, branded in the US. illumetTM has demonstrated considerable impact on patient care and demand for better imaging technology to manage metastatic prostate cancer, resulting in the rapid commercialisation of the product. European Urology Association (EAU) formally adopted PSMA imaging with Positron Emission Tomography (PET) as standard care, paving the way for the Telix/ANMI prostate cancer imaging product in Europe.
The announcement read that in the next half of year, TLX shall have a lot to hear from the FDA with respect to a new drug application (NDA) submission for the prostate cancer program, ZIRCON trial and a prospective Phase III trial for prostate cancer therapy program. TLX expects advancement in renal cancer therapy programs and glioblastoma therapy program before the end of 2019.
Multiple Milestones and Readouts in 2019 (Source: Companyâs Announcement)
It was asserted that progress of TLX must be considered against a backdrop of an overall industry performance. The market trends outline the increased focus and attention from mainstream oncology for both imaging and therapeutic applications with Nuclear medicine starting to hit its stride.
TLX settled at A$0.915 on 22 May 2019, up 4.58% from the prior close. The 52-week high and low are A$0.54 and A$1.03, respectively.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
